Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, the company manufactures and distributes medical products for reproductive medicine; manufactures bespoke workstations, incubators, and equipment for IVF laboratories; researches, designs, develops, sells, installs, and services in-vitro diagnostic systems; and manufactures ovum pickup needles, catheters, and other devices. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as capital equipment and consumables, software, and other services. It sells its products and services under Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, MICROPTIC, Gynétics, and Embryotech brand names through a direct sales force in the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 100 countries. Hamilton Thorne Ltd. is headquartered in Beverly, Massachusetts.
U.S. Market Performance
7D7 Days: 0.9%
3M3 Months: 23.0%
1Y1 Year: 14.8%
YTDYear to Date: 6.9%
In the last week, the market has been flat, with a notable exception in the Energy sector dropping 3.3%. More promisingly, the market is up 15% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.